Cytochrome P450 BM3 mutant and its use

By performing specific amino acid mutations on the P450 BM3 enzyme, a cytochrome P450 BM3 mutant with high catalytic activity and selectivity was constructed, which solved the problems of low biological activity and poor selectivity during the MDCA generation process in the prior art, and achieved steroids The efficient 6β hydroxylation of the compound meets the needs of industrial production.

CN118755681BInactive Publication Date: 2024-11-08SOUTH CHINA UNIV OF TECH
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202411218110.5
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2024-09-02
Publication Date
2024-11-08
Estimated Expiration
Not applicable · inactive patent

AI Technical Summary

Technical Problem

The existing cytochrome CYP107D1 and P450 BM3 enzyme mutant LG-23 has problems with low biological activity and poor selectivity during the catalyzing of murine deoxycholic acid (MDCA), which cannot meet the needs of industrial production.

Method used

By performing specific amino acid mutations on the amino acid sequence of the P450 BM3 enzyme mutant, a cytochrome P450 BM3 mutant with excellent selectivity and high catalytic activity, such as T260G+G328A+L82V, is used to catalyze the 6β hydroxylation reaction of steroid compounds .

Benefits of technology

It has achieved efficient 6β hydroxylation of steroid compounds, significantly improved conversion rate and selectivity, and has good application prospects, providing feasible solutions for industrial production.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118755681B_ABST
    Figure CN118755681B_ABST
Patent Text Reader

Abstract

The present application proposes a cytochrome P450 BM3 mutant and its use. The mutant undergoes an amino acid mutation in the amino acid sequence shown in SEQ ID NO.2. The present application example uses the amino acid sequence shown in SEQ ID NO.2 as a template, performs mutation modification on the key active sites of the template, constructs a mutant library, and screens a series of mutants with significantly improved catalytic activity and / or selectivity; the cytochrome P450 BM3 mutant provided in the present application example can selectively catalyze steroid compounds to undergo 6β-hydroxylation reaction to generate 6β-hydroxylated steroid compounds, and has excellent selectivity and / or high yield, suggesting that the mutant has good application prospects in catalyzing steroid compounds to prepare 6β-hydroxy steroid compounds.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present application relates to the field of biological enzyme technology, and in particular to a cytochrome P450 BM3 mutant and its use. Background Art

[0002] Murideoxycholic acid (MDCA), also known as 3α, 6β-dihydroxy-5β-cholestane-24-acid; existing studies have shown that MDCA can dissolve gallstones and prevent gallstone formation.

[0003] At present, MDCA is mainly extracted from the bile of rodents; therefore, there is an urgent need to provide other effective synthetic pathways to prepare MDCA. Among them, Sascha Grobe et al. reported that cytochrome CYP107D1 (Olep) can catalyze lithocholic acid (LCA) to MDCA (Grobe, S., Wszołek, A., Brundiek, H. et al. Highly selective bile acid hydroxylation by the multifunctional bacterial P450 monooxygenaseCYP107D1 (OleP) [J]. Biotechnol Lett, 2020, 42(5): 819–824.). However, the enzyme-catalyzed reaction has the problems of low biological activity and / or poor selectivity, which cannot meet the needs of large-scale industrial production.

[0004] P450 BM3 is from Bacillus subtilis ( Bacillus megaterium ) is a P450 enzyme that is widely used in the synthesis of various chemicals because of its higher catalytic activity than other P450 enzymes. In the prior art, the P450 BM3 enzyme mutant LG-23 (Li A, Acevedo-Rocha CG, D'Amore L, et al.Regio- and Stereoselective Steroid Hydroxylation at the C7-Position byCytochrome P450 Monooxygenase Mutants[J]. Angewandte Chemie, 2020, 59(30):12499-12505.) with steroid 7β hydroxylation activity can catalyze the C7 hydroxylation of sterols, but the reaction of LG-23 catalyzing LCA to MDCA has the problems of low conversion rate and / or poor selectivity.

[0005] In view of this, modifying the structure of the P450 BM3 enzyme mutant LG-23 to achieve efficient synthesis of MDCA is of great significance for promoting the industrial production of MDCA. Summary of the invention

[0006] The purpose of the present application is to provide a cytochrome P450 BM3 mutant and its use.

[0007] To achieve the above objectives, the present application proposes the following technical solutions:

[0008] In a first aspect, the present invention provides a cytochrome P450 BM3 mutant, wherein the mutant has any one of the following amino acid mutations in the amino acid sequence shown in SEQ ID NO. 2:

[0009] T260G, T260G+G328A, T260G+G328S, T260G+W330F, T260G+W330V, T260G+L437M, T260G+T438A, T260G+T 438G, T260G+T438S, T260G+T438V, T260G+W72G, T260G+L78A, T260G+L78S, T260G+L82G, T260G+G328A+W 330A, T260G+G328A+W330D, T260G+G328A+W330F, T260G+G328A+W330G, T260G+G328A+W330I, T260G+G3 28A+W330L, T260G+G328A+W330M, T260G+G328A+W330N, T260G+G328A+W330S, T260G+G328A+W330V, T260 G+G328A+W330Y, T260G+G328A+T438A, T260G+G328A+T438D, T260G+G328A+T438G, T260G+G328A+T438S , T260G+G328A+T438V, T260G+G328A+W72C, T260G+G328A+W72I, T260G+G328A+A74D, T260G+G328A+A74G , T260G+G328A+L82C, T260G+G328A+L82D, T260G+G328A+L82F, T260G+G328A+L82G, T260G+G328A+L82I , T260G+G328A+L82M, T260G+G328A+L82N, T260G+G328A+L82S, T260G+G328A+L82T, T260G+G328A+L82V.

[0010] In a second aspect, an embodiment of the present application provides a DNA molecule comprising a nucleotide sequence encoding the cytochrome P450 BM3 mutant as described in the first aspect or its complementary sequence.

[0011] In a third aspect, an embodiment of the present application provides a recombinant plasmid, wherein the recombinant plasmid contains the DNA molecule as described in the second aspect.

[0012] In a fourth aspect, an embodiment of the present application provides a recombinant strain, wherein the recombinant strain contains the recombinant plasmid as described in the third aspect.

[0013] In the fifth aspect, the embodiments of the present application provide the use of the cytochrome P450 BM3 mutant described in the first aspect, the DNA molecule described in the second aspect, the recombinant plasmid described in the third aspect, and the recombinant strain described in the fourth aspect for catalyzing the 6β-hydroxylation reaction of steroid compounds to generate 6β-hydroxylated steroid compounds.

[0014] As an embodiment, the preparation method of the 6β-hydroxylated steroid compound comprises:

[0015] preparing a recombinant plasmid containing a gene encoding a cytochrome P450 BM3 mutant;

[0016] Transforming the recombinant plasmid into a host cell to obtain a recombinant strain;

[0017] Using steroidal compounds as substrates, in the presence of O2 and NADPH, the recombinant strain catalyzes 6β-hydroxylation of steroidal compounds to obtain 6β-hydroxylated steroidal compounds;

[0018] The steroid compound is selected from one of the following compounds:

[0019] ;

[0020] Wherein, R1, R2, and R3 are selected from any one of the following AK:

[0021] .

[0022] The embodiments of the present application have at least the following beneficial effects:

[0023] The example of the present application uses the amino acid sequence shown in SEQ ID NO. 2 as a template (basis), performs mutation modification on the key active sites of the template (basis), constructs a mutant library, and screens to obtain a series of mutants with significantly improved catalytic activity and / or selectivity; the cytochrome P450 BM3 mutant provided in the example of the present application can selectively catalyze the 6β-hydroxylation reaction of steroid compounds to generate 6β-hydroxylated steroid compounds, and has excellent selectivity and / or high yield, indicating that the mutant has good application prospects in catalyzing steroid compounds to prepare 6β-hydroxysteroid compounds.

[0024] Additional aspects and advantages of the present application will be partially given in the following description, which will become apparent from the following description, or will be understood through the practice of the present application. BRIEF DESCRIPTION OF THE DRAWINGS

[0025] Figure 1 The schematic diagram of the reaction of cytochrome P450 BM3 mutant catalyzing LCA to MDCA;

[0026] Figure 2 HPLC chart of LCA catalyzed by template LG-23;

[0027] Figure 3 This is the HPLC chart of LCA catalyzed by mutant T260G+G328A+L82V. DETAILED DESCRIPTION

[0028] The technical solutions in the embodiments will be described clearly and completely below in combination with the embodiments and drawings of the present application. Obviously, the embodiments described below are only part of the embodiments of the present application, rather than all of the embodiments. Based on the embodiments in the present application, all other embodiments obtained by ordinary technicians in this field without creative work are within the scope of protection of this application.

[0029] It should be understood that when used in this specification and the appended claims, the terms "include" and "comprises" indicate the presence of described features, integers, steps, operations, elements and / or components, but do not exclude the presence or addition of one or more other features, integers, steps, operations, elements, components and / or combinations thereof.

[0030] It should also be understood that the terms used in this specification of the embodiments of the present application are only for the purpose of describing specific embodiments and are not intended to limit the embodiments of the present application. As used in the specification of the embodiments of the present application and the appended claims, unless the context clearly indicates otherwise, the singular forms of "a", "an" and "the" are intended to include plural forms.

[0031] Some of the terms and materials involved in this embodiment are explained below to facilitate understanding by those skilled in the art.

[0032] LCA: Lithocholic acid, English name is Lithocholic acid; the structural formula of LCA is:

[0033] .

[0034] MDCA: Murideoxycholic acid, English name is Murideoxycholic acid; the structural formula of MDCA is: .

[0035] The cytochrome P450 BM3 mutants and their uses according to the examples of the present application will be described in detail below.

[0036] First, the cytochrome P450 BM3 mutant of this example is described.

[0037] Cytochrome P450 BM3 mutant

[0038] In the prior art, cytochrome P450 BM3 is widely used in the synthesis of various chemicals because of its higher catalytic activity than other P450 enzymes. For example, the P450 BM3 enzyme mutant LG-23 (having an amino acid sequence as shown in SEQ ID NO. 2) with steroid 7β hydroxylation activity can catalyze the C7 hydroxylation of sterols, but the reaction of LG-23 catalyzing LCA to MDCA has the problems of low conversion rate and / or poor selectivity.

[0039] In view of this, this embodiment provides a cytochrome P450 BM3 mutant; specifically, the mutant of this embodiment has any one of the following amino acid mutations in the amino acid sequence shown in SEQ ID NO. 2:

[0040] T260G, T260G+G328A, T260G+G328S, T260G+W330F, T260G+W330V, T260G+L437M, T260G+T438A, T260G+T 438G, T260G+T438S, T260G+T438V, T260G+W72G, T260G+L78A, T260G+L78S, T260G+L82G, T260G+G328A+W 330A, T260G+G328A+W330D, T260G+G328A+W330F, T260G+G328A+W330G, T260G+G328A+W330I, T260G+G3 28A+W330L, T260G+G328A+W330M, T260G+G328A+W330N, T260G+G328A+W330S, T260G+G328A+W330V, T260 G+G328A+W330Y, T260G+G328A+T438A, T260G+G328A+T438D, T260G+G328A+T438G, T260G+G328A+T438S , T260G+G328A+T438V, T260G+G328A+W72C, T260G+G328A+W72I, T260G+G328A+A74D, T260G+G328A+A74G , T260G+G328A+L82C, T260G+G328A+L82D, T260G+G328A+L82F, T260G+G328A+L82G, T260G+G328A+L82I , T260G+G328A+L82M, T260G+G328A+L82N, T260G+G328A+L82S, T260G+G328A+L82T, T260G+G328A+L82V.

[0041] Among them, the amino acid sequence of cytochrome P450 BM3 (SEQ ID NO. 2) is:

[0042]

[0043] It can be understood that this embodiment uses the amino acid sequence shown in SEQ ID NO. 2 as a template (basis), and on the basis of this amino acid sequence, the key active site of the cytochrome P450 BM3 is mutated and modified to construct a mutant library; the cytochrome P450 BM3 mutant provided in this embodiment can selectively catalyze the 6β-hydroxylation reaction of steroid compounds to generate corresponding 6β-hydroxylated steroid compounds, and has excellent selectivity and / or high yield.

[0044] In this example, the nucleotide sequence of cytochrome P450 BM3 is shown in SEQ ID NO. 1, and the amino acid sequence is shown in the above SEQ ID NO. 2.

[0045] The nucleotide sequence of the above cytochrome P450 BM3 (SEQ ID NO. 1) is:

[0046]

[0047] As a preferred embodiment of this embodiment, the mutant of this embodiment has any one of the following amino acid mutations in the amino acid sequence shown in SEQ ID NO. 2:

[0048] T260G+G328A, T260G+W330F, T260G+W330V, T260G+T438A, T260G+T438S, T260G+ T438V, T260G+W72G, T260G+L82G, T260G+G328A+W330A, T260G+G328A+W330D, T26 0G+G328A+W330F, T260G+G328A+W330G, T260G+G328A+W330I, T260G+G328A+W330 L. T260G+G328A+W330M, T260G+G328A+W330N, T260G+G328A+W330S, T260G+G328A +W330V, T260G+G328A+W330Y, T260G+G328A+T438A, T260G+G328A+T438D, T260G +G328A+T438G, T260G+G328A+T438V, T260G+G328A+W72C, T260G+G328A+A74G, T2 60G+G328A+L82C, T260G+G328A+L82F, T260G+G328A+L82G, T260G+G328A+L82I, T 260G+G328A+L82M, T260G+G328A+L82N, T260G+G328A+L82T, T260G+G328A+L82V.

[0049] It is understandable that the cytochrome P450 BM3 mutant of this embodiment can be mutated at the corresponding site by existing site-directed mutagenesis technology to obtain the target mutant. Among them, the mutant with multiple mutation points can be superimposed on the basis of a single mutant, that is, on the basis of a single mutant, a mutation is performed at another amino acid mutation site to obtain a mutant with multiple mutation points.

[0050] In summary, the cytochrome P450 BM3 mutant provided in this example can catalyze the 6β-hydroxylation reaction of various steroid compounds with excellent selectivity and / or high yield, indicating that the mutant has good application prospects in the preparation of 6β-hydroxysteroid compounds (6β-hydroxylation products) from steroid compounds by enzyme-catalyzed steroid compounds.

[0051] It should be understood that the mutants provided in this embodiment can improve the selectivity of steroid compounds to generate 6β-hydroxysteroid compounds alone, can also improve the yield of steroid compounds to generate 6β-hydroxysteroid compounds alone, or can simultaneously improve the selectivity and yield of steroid compounds to generate 6β-hydroxysteroid compounds.

[0052] The selectivity is defined as 6β-hydroxylation product / total product × 100%; the conversion rate is defined as: (initial substrate concentration-substrate concentration at the end of the reaction) / initial substrate concentration × 100%.

[0053] The mutant provided in this example is not limited to catalyzing lithocholic acid (LCA) to produce murideoxycholic acid (MDCA), and the mutant can also catalyze the 6β-hydroxylation reaction of other steroid compounds.

[0054] Next, the use of the above-mentioned cytochrome P450 BM3 mutant will be described.

[0055] Recombinant plasmid

[0056] The recombinant plasmid provided in this embodiment is a DNA molecule containing a nucleotide sequence encoding any of the above-mentioned cytochrome P450 BM3 mutants or its complementary sequence.

[0057] Illustratively, the recombinant plasmid of this embodiment can be selected from any one of the following:

[0058] pQE2, pQE9, pQE30, pQE31, pQE32, pQE40, pQE70, pQE80, pRSET-A, pRSET-B, pRSET- C. pGEX-5X-1, pGEX-6p-1, pGEX-6p-2, pBV220, pBV221, pBV222, pTrc99A, pTwin1, pEZZ18, pKK232-8, pUC-18, pUC-19, pET-21b (+), pET-22b (+), pET-3a (+), pET-3d (+), pET-11a (+), pET-12a (+), pET-14b, pET-15b (+), pET-16b (+), pET-17b (+), pE T-19b(+), pET-20b(+), pET-21a(+), pET-23a(+), pET-23b(+), pET-24a(+), pET- 25b(+), pET-26b(+), pET-27b(+), pET-28a(+), pET-29a(+), pET-30a(+), pET-31 b(+), pET-32a(+), pET-35b(+), pET-38b(+), pET-39b(+), pET-40b(+), pET-41a( +), pET-41b (+), pET-42a (+), pET-43a (+), pET-43b (+), pET-44a (+), pET-49b (+).

[0059] It is understandable that the recombinant plasmid of this embodiment can be prepared by a known preparation method, for example:

[0060] Using the expression vector containing the amino acid sequence shown in SEQ ID NO. 2 as a template, mutations were performed at the corresponding sites to obtain a recombinant plasmid containing the encoding cytochrome P450 BM3 mutant.

[0061] Among them, the above-mentioned expression vector can be selected from pET-28a; the above-mentioned expression vector containing the amino acid sequence shown in SEQ ID NO. 2 can be synthesized into the pET-28a vector by a gene synthesis company (such as Tianyi Huiyuan Gene Technology Co., Ltd.) to obtain the corresponding template (such as pET28a-LG-23 in the following Example 1).

[0062] Recombinant strains

[0063] It is understandable that the recombinant strain provided in this embodiment contains the above-mentioned recombinant plasmid.

[0064] In this embodiment, the host cell of the recombinant strain is a prokaryotic cell or a eukaryotic cell, and preferably the eukaryotic cell is a yeast cell.

[0065] The host cell may be a competent cell, and the competent cell is preferably Escherichia coli BL21 (DE3).

[0066] The recombinant strain of this embodiment can be prepared by the following preparation method, for example:

[0067] The prepared recombinant plasmid was transferred into Escherichia coli BL21 (DE3) for cultivation to obtain a recombinant strain.

[0068] The prepared recombinant strain usually needs to be stored in a refrigerator (such as -80°C).

[0069] Uses of cytochrome P450 BM3 mutants

[0070] As mentioned above, the cytochrome P450 BM3 mutant of this example can be used to catalyze the 6β-hydroxylation reaction of steroid compounds to generate 6β-hydroxylated steroid compounds.

[0071] It is understandable that, based on the use of the cytochrome P450 BM3 mutant, the DNA molecule, recombinant plasmid, and host cell of this example can also be used to catalyze the 6β-hydroxylation reaction of steroid compounds to generate 6β-hydroxylated steroid compounds.

[0072] The preparation method of 6β-hydroxylated steroidal compounds will be described in detail below.

[0073] Illustratively, the method for preparing a 6β-hydroxylated steroid compound in this embodiment comprises:

[0074] (1) preparing a recombinant plasmid encoding a cytochrome P450 BM3 mutant;

[0075] (2) transforming the recombinant plasmid into a host cell to obtain a recombinant strain;

[0076] (3) using steroidal compounds as substrates, in the presence of O2 and NADPH, using the recombinant strain to catalyze 6β-hydroxylation of the steroidal compounds to obtain 6β-hydroxylated steroidal compounds;

[0077] The steroid compound is selected from one of the following compounds: ;

[0078] Wherein, R1, R2, and R3 are selected from any one of the following AK:

[0079] .

[0080] The steps of the above preparation method will be further described below.

[0081] In step (1), preparing a recombinant plasmid encoding a cytochrome P450 BM3 mutant comprises:

[0082] Using the expression vector containing the amino acid sequence shown in SEQ ID NO. 2 as a template, mutations (site-directed mutagenesis) were performed at the corresponding sites to obtain a recombinant plasmid containing the encoding cytochrome P450 BM3 mutant.

[0083] Among them, site-directed mutagenesis can adopt existing mutagenesis techniques, such as polymerase chain reaction (PCR) method.

[0084] In step (3), the steroid compound is used as a substrate, and in the presence of O2 and NADPH, the recombinant strain is used to catalyze the 6β-hydroxylation of the steroid compound to obtain the 6β-hydroxylated steroid compound, comprising:

[0085] The obtained recombinant bacteria were inoculated into TB liquid culture medium, and the bacteria were collected by centrifugation after shaking culture;

[0086] The bacteria were resuspended in a buffer (100 mM potassium phosphate buffer, pH=7.2), and a steroid compound was added to react in the presence of O2 and NADPH to obtain a product 6β-hydroxylated steroid (6β-hydroxylated steroid compound).

[0087] Among them, the above reaction requires the participation of oxygen so that the cytochrome P450 BM3 mutant can catalyze steroid compounds to generate corresponding 6β-hydroxylated steroid compounds, so the reaction can be carried out directly in an air environment; at the same time, NADPH is an electron donor and a condition for the cytochrome P450 BM3 mutant to be active, so the reaction usually needs to be carried out in a NADPH regeneration and reduction system.

[0088] It can be understood that the steroid compound described in this embodiment is the substrate of the reaction.

[0089] For example, when R1, R2, and R3 are selected from the groups shown in A above, the steroid compound is LCA; see Figure 1 In this example, the cytochrome P450 BM3 mutant can selectively catalyze the steroid compound LCA to directly undergo 6β-hydroxylation to obtain the corresponding 6β-hydroxylated steroid compound, namely MDCA.

[0090] Therefore, the cytochrome P450 BM3 mutant provided in this example can catalyze the 6β-hydroxylation reaction of various steroid compounds with excellent selectivity and / or high yield, indicating that the mutant has good application prospects in the preparation of 6β-hydroxysteroid compounds (6β-hydroxylation products) from steroid compounds by enzyme-catalyzed steroid compounds.

[0091] The present application will be further described below in conjunction with specific embodiments. It should be understood that these embodiments are only used to illustrate / explain the present application and are not used to limit the scope of the present application.

[0092] In the following examples, the materials, reagents and instruments used can be purchased from commercial sources unless otherwise specified.

[0093] It should be noted that, in the following examples, unless otherwise specified, the reaction buffer is: 100 mM potassium phosphate buffer, pH = 7.2; the equilibrium buffer is: 40 mM sodium phosphate buffer, 500 mM NaCl, 20 mM imidazole, pH = 7.2; and the elution buffer is: 40 mM sodium phosphate buffer, 500 mM NaCl, 500 mM imidazole, pH = 7.2.

[0094] Embodiment 1:

[0095] Synthesis and recombinant expression of template pET28a-LG-23

[0096] This example uses the LG-23 mutant (Li A, Acevedo-Rocha CG, D'Amore L, et al. Regio- and Stereoselective SteroidHydroxylation at the C7-Position by Cytochrome P450 Monooxygenase Mutants[J]. Angewandte Chemie, 2020, 59(30): 12499-12505.) reported in the literature as a template with 7β-hydroxylation activity for testosterone; in view of the fact that the template LG-23 has the problem of low conversion rate and / or poor selectivity in the reaction of catalyzing LCA to generate MDCA. In this example, LG-23 is used as a parent template to synthesize and recombinantly express the template pET28a-LG-23; the nucleotide sequence of the parent template LG-23 is shown in SEQ ID NO. 1, and the amino acid sequence is shown in SEQ ID NO. 2;

[0097] Specifically:

[0098] The gene sequence of LG-23 was synthesized into the pET28a vector and named pET28a-LG-23;

[0099] Transform pET28a-LG-23 into E. coli BL21 (DE3):

[0100] Take out the E. coli BL21 (DE3) competent cells from the -80℃ refrigerator and quickly place them on ice to allow them to thaw naturally. Add 2 μL of plasmid to the thawed competent cells and place them on ice for 30 min. Transfer the competent cells to a 42℃ water bath and perform heat shock treatment for about 90 s; then immediately place them on ice for 2 min.

[0101] Add 600 μL of resistance-free LB liquid medium (100 mL LB liquid medium: 1.0 g peptone, 1.0 g sodium chloride, 0.5 g yeast powder) into the clean bench and culture in a constant temperature incubator at 37°C and 180 rpm for 1 h. After the culture was completed, 50 μL of the culture solution was spread on LB solid medium containing 50 μg / mL Kana resistance (100 mL LB solid medium: 1.0 g peptone, 1.0 g sodium chloride, 0.5 g yeast powder, 1.5 g agar powder), and incubated inverted in a 37°C incubator overnight; a single colony on the plate was picked for activation and inoculated into 25 mL TB medium containing Kanamycin (100 mL TB medium: 1.2 g peptone, 2.4 g yeast powder, 0.4 mL glycerol, 0.231 g anhydrous potassium dihydrogen phosphate, 1.643 g dipotassium hydrogen phosphate trihydrate) and incubated at 37°C, 220 rpm until the OD 600 0.6-0.8, add inducer IPTG 0.2 mM and 5-ALA 0.5 mM, and culture at 25°C, 180 rpm shaking for 20 h;

[0102] The cells were collected at 6000 rpm, 4°C, for 10 min, and the collected cells were washed twice with reaction buffer. The washed cells (wet cells) were stored in a -80°C refrigerator for later use.

[0103] Embodiment 2:

[0104] Construction of cytochrome P450 BM3 mutant

[0105] Using pET28a-LG-23 plasmid as template, design mutation primers, and place the base to be mutated in the middle of the primer;

[0106] PCR amplification system (50 μL): template 1 ng, upstream and downstream primers 1.5 μL each, 2×PCR Buffer for KODFX Neo 25 μL, KOD FX Neo enzyme 1 μL, and finally add sterile distilled water to make up the volume to 50 μL;

[0107] The sequences of the upstream and downstream mutation primers used in this example are shown in Table 1 below:

[0108] Table 1: Sequences of upstream and downstream mutation primers

[0109] Primer name Primer sequence (5'-3') W72A-F GATAAAAATCTGGCACAGGCACTGAAATATCTGCGTG W72A-R GCAGATATTTCAGTGCCTGTGCCAGATTTTTATCAAAACGGC L75A-F GATAAAAATCTGTGGCAGGCAGCGAAATATCTGCGTGATATTCTGG L75A-R CACGCAGATATTTCGCTGCCTGCCACAGATTTTTATCAAAAC L82G-F GAAATATCTGCGTGATATTGGTGGTGATGGTCTGGGTAGCAG L82G-R CAGACCATCACCACCAATATCACGCAGATATTTCAGTGCC T260G-F GTTATCAGATTATTGGTTTTCTGATTGCAGGTCATGAAACCACCAG T260G-R GACCTGCAATCAGAAAACCAATAATCTGATAACG W330F-F1 GGCCGACCGGTCCGTTTTTTAGCCTGTATGCAAAAGAAG W330F-R1 CTTTTGCATACAGGCTAAAAAACGGACCGGTCGGCCACAGAC W330F-F2 GGCCGACCGCACCGTTTTTTAGCCTGTATGCAAAAGAAG W330F-R2 CTTTTGCATACAGGCTAAAAAACGGTGCGGTCGGCCACAGAC G328A-F GTCTGTGGCCGACCGCACCGTGGTTTAGCCTGTATGCAAAAG G328A-R CTAAACCACGGTGCGGTCGGCCACAGACGGCAGTGCTTCATTCAGAAC G328S-F GTCTGTGGCCGACCAGCCCGTGGTTTAGCCTGTATGCAAAAG G328S-R CTAAACCACGGTGCGGTCGGCCACAGACGGCAGTGCTTCATTCAGAAC W330V-F1 GGCCGACCGGTCCGGTTTTTAGCCTGTATGCAAAAGAAG W330V-R1 CTTTTGCATACAGGCTAAAAACCGGACCGGTCGGCCACAGAC W330V-F2 GGCCGACCGCACCGGTTTTTAGCCTGTATGCAAAAGAAG W330V-R2 CTTTTGCATACAGGCTAAAAACCGGTGCGGTCGGCCACAGAC L437M-F GGATATTAAAGAAACCATGACCCTGAAACCGGAAGG L437M-R CCGGTTTCAGGGTCATGGTTTCTTTAATATCCAGTTC T438A-F GATATTAAAGAAACCCTGGCGCTGAAACCGGAAGGTTTTGTTG T438A-R CCTTCCGGTTTCAGCGCCAGGGTTTCTTTAATATCCAGTTCATAATTG T438G-F GATATTAAAGAAACCCTGGGTCTGAAACCGGAAGGTTTTGTTG T438G-R CCTTCCGGTTTCAGACCCAGGGTTTCTTTAATATCCAGTTCATAATTG T438S-F GATATTAAAGAAACCCTGAGCCTGAAACCGGAAGGTTTTGTTG T438S-R CCTTCCGGTTTCAGGCTCAGGGTTTCTTTAATATCCAGTTCATAATTG T438V-F GATATTAAAGAAACCCTGGTTCTGAAACCGGAAGGTTTTGTTG T438V-R CCTTCCGGTTTCAGAACCAGGGTTTCTTTAATATCCAGTTCATAATTG W72G-F GATAAAAATCTGGGTCAGGCACTGAAATATCTGCGTG W72G-R GCAGATATTTCAGTGCCTGACCCAGATTTTTATCAAAACGGC L78A-F GGCACTGAAATATGCGCGTGATATTCTGGGTGATGGTCTG L78A-R CAGAATATCACGCGCATATTTCAGTGCCTGCCACAG L78S-F GGCACTGAAATATAGCCGTGATATTCTGGGTGATGGTCTG L78S-R CAGAATATCACGGCTATATTTCAGTGCCTGCCACAG W330A-F GGCCGACCGCACCGGCATTTAGCCTGTATGCAAAAGAAG W330A-R CTTTTGCATACAGGCTAAATGCCGGTGCGGTCGGCCACAGAC W330D-F GGCCGACCGCACCGGATTTTAGCCTGTATGCAAAAGAAG W330D-R CTTTTGCATACAGGCTAAAATCCGGTGCGGTCGGCCACAGAC W330G-F GGCCGACCGCACCGGGTTTTAGCCTGTATGCAAAAGAAG W330G-R CTTTTGCATACAGGCTAAAACCCGGTGCGGTCGGCCACAGAC W330I-F GGCCGACCGCACCGATTTTTAGCCTGTATGCAAAAGAAG W330I-R CTTTTGCATACAGGCTAAAAATCGGTGCGGTCGGCCACAGAC W330L-F GGCCGACCGCACCGCTGTTTAGCCTGTATGCAAAAGAAG W330L-R CTTTTGCATACAGGCTAAACAGCGGTGCGGTCGGCCACAGAC W330M-F GGCCGACCGCACCGATGTTTAGCCTGTATGCAAAAGAAG W330M-R CTTTTGCATACAGGCTAAACATCGGTGCGGTCGGCCACAGAC W330N-F GGCCGACCGCACCGAATTTTAGCCTGTATGCAAAAGAAG W330N-R CTTTTGCATACAGGCTAAAATTCGGTGCGGTCGGCCACAGAC W330S-F GGCCGACCGCACCGAGCTTTAGCCTGTATGCAAAAGAAG W330S-R CTTTTGCATACAGGCTAAAGCTCGGTGCGGTCGGCCACAGAC W330Y-F GGCCGACCGCACCGTATTTTAGCCTGTATGCAAAAGAAG W330Y-R CTTTTGCATACAGGCTAAAATACGGTGCGGTCGGCCACAGAC T438D-F GATATTAAAGAAACCCTGGATCTGAAACCGGAAGGTTTTGTTG T438D-R CCTTCCGGTTTCAGATCCAGGGTTTCTTTAATATCCAGTTCATAATTG W72C-F GATAAAAATCTGTGTCAGGCACTGAAATATCTGCGTG W72C-R GCAGATATTTCAGTGCCTGACACAGATTTTTATCAAAACGGC W72I-F GATAAAAATCTGATTCAGGCACTGAAATATCTGCGTG W72I-R GCAGATATTTCAGTGCCTGAATCAGATTTTTATCAAAACGGC A74D-F GATAAAAATCTGGATCAGGCACTGAAATATCTGCGTG A74D-R GCAGATATTTCAGTGCCTGATCCAGATTTTTATCAAAACGGC A74G-F GATAAAAATCTGGTTCAGGCACTGAAATATCTGCGTG A74G-R GCAGATATTTCAGTGCCTGAACCAGATTTTTATCAAAACGGC L82C-F GAAATATCTGCGTGATATTTGTGGTGATGGTCTGGGTAGCAG L82C-R CAGACCATCACCACAAATATCACGCAGATATTTCAGTGCC L82D-F GAAATATCTGCGTGATATTGATGGTGATGGTCTGGGTAGCAG L82D-R CAGACCATCACCATCAATATCACGCAGATATTTCAGTGCC L82F-F GAAATATCTGCGTGATATTTTTGGTGATGGTCTGGGTAGCAG L82F-R CAGACCATCACCAAAAATATCACGCAGATATTTCAGTGCC L82I-F GAAATATCTGCGTGATATTATTGGTGATGGTCTGGGTAGCAG L82I-R CAGACCATCACCAATAATATCACGCAGATATTTCAGTGCC L82M-F GAAATATCTGCGTGATATTATGGGTGATGGTCTGGGTAGCAG L82M-R CAGACCATCACCCATAATATCACGCAGATATTTCAGTGCC L82N-F GAAATATCTGCGTGATATTAATGGTGATGGTCTGGGTAGCAG L82N-R CAGACCATCACCATTAATATCACGCAGATATTTCAGTGCC L82S-F GAAATATCTGCGTGATATTAGCGGTGATGGTCTGGGTAGCAG L82S-R CAGACCATCACCGCTAATATCACGCAGATATTTCAGTGCC L82T-F GAAATATCTGCGTGATATTACCGGTGATGGTCTGGGTAGCAG L82T-R CAGACCATCACCGGTAATATCACGCAGATATTTCAGTGCC L82V-F GAAATATCTGCGTGATATTGTCGGTGATGGTCTGGGTAGCAG L82V-R CAGACCATCACCGACAATATCACGCAGATATTTCAGTGCC

[0110] Note: In Table 1, W330F-F1 and W330F-R1 are the upstream and downstream mutation primers of mutant (single mutation point) W330F and mutant T260G+W330F; W330F-F2 and W330F-R2 are the upstream and downstream mutation primers of W330F in mutant T260G+G328A+W330F; W330V-F1 and W330V-R1 are the upstream and downstream mutation primers of W330V in mutant T260G+W330V; W330V-F2 and W330V-R2 are the upstream and downstream mutation primers of W330V in mutant T260G+G328A+W330V;

[0111] PCR reaction procedure: (1) pre-denaturation at 94°C for 2 min; (2) denaturation at 98°C for 10 s; (3) annealing temperature set according to the mutant primer, annealing time 15 s; (4) extension at 68°C for 4 min 20 s, steps (2) to (4) were repeated 30 times, and finally extension at 68°C for 10 min, and PCR products were stored at 12°C;

[0112] The above PCR products were digested with Dpn I enzyme, and after removing the template, they were transferred into E. coli DH5α competent cells. The recovered bacterial solution was spread on LB medium plates containing 50 μg / mL kanamycin, and incubated at 37°C overnight. Single clones were picked for single colony verification, and 1-3 single colonies were selected for gene sequencing;

[0113] Among them, mutants with multiple mutation points are obtained by superimposing mutations on a single mutant using the same method as above;

[0114] The inducible expression of the mutants was consistent with that of the above templates.

[0115] Embodiment 3:

[0116] Activity screening of mutants

[0117] In this example, LCA was used as an exemplary substrate to determine the catalytic activity of the mutants;

[0118] The wet cells obtained above were resuspended according to 1 g (wet cells): 15 mL (reaction buffer), and 900 μL was used for ultrasonic disruption, with 1 s of disruption and 2 s of rest, for a total of 10 min. The disrupted liquid was centrifuged at 12000 rpm for 15 min. The supernatant was collected and added with 1 mM substrate LCA (prepared with methanol to 100 mM stock solution), 1 mg / mL glucose dehydrogenase, 100 mM glucose, and 1 mM NADP. + , final volume 1 mL;

[0119] In an air environment, place at 20°C and 220 rpm for 12-24 h. After the reaction is completed, take an equal volume of ethyl acetate for extraction, repeat the extraction three times, and finally combine the organic phases, use rotary evaporation to dry the solvent, and then redissolve it with 1 mL of methanol, filter it with a 0.22 μm organic filter membrane, and use HPLC for detection. The activity test results of the mutants are shown in Table 2 below:

[0120] Table 2: Activity test results of mutants

[0121] Mutants Conversion rate (%) Selectivity(%) WT(LG-23) 8.0±2.4 62.0±4.2 W72A 1.0±0.3 99.3±0.2 L75A 1.3±0.6 99.4±0.4 L82G 3.2±1.5 99.3±0.1 T260G 16.5±1.6 94.4±4.0 W330F 9.5±0.4 42.8±1.9 T260G+G328A 34.1±1.3 96.9±0.3 T260G+G328S 8.3±0.3 98.8±1.2 T260G+W330F 27.2±1.3 84.0±4.9 T260G+W330V 26.2±5.2 81.4±2.1 T260G+L437M 18.3±5.1 77.3±0.8 T260G+T438A 21.2±3.3 93.4±4.2 T260G+T438G 8.4±4.3 99.2±0.8 T260G+T438S 26.7±1.2 97.9±1.4 T260G+T438V 24.0±5.4 75.2±0.2 T260G+W72G 20.0±5.8 80.5±2.9 T260G+L78A 12.8±0.3 73.6±0.4 T260G+L78S 13.1±0.8 77.8±1.3 T260G+L82G 23.9±5.0 72.7±1.5 T260G+G328A+W330A 49.6±2.8 96.1±2.3 T260G+G328A+W330D 32.8±3.3 81.3±1.1 T260G+G328A+W330F 32.3±21.2 95.9±1.7 T260G+G328A+W330G 39.4±1.0 96.8±2.2 T260G+G328A+W330I 34.5±0.3 80.5±3.8 T260G+G328A+W330L 31.7±1.8 79.1±0.3 T260G+G328A+W330M 35.9±3.0 81.3±0.3 T260G+G328A+W330N 34.8±2.4 80.7±3.5 T260G+G328A+W330S 57.4±1.7 94.3±2.1 T260G+G328A+W330V 52.5±1.3 97.0±0.7 T260G+G328A+W330Y 23.8±3.1 68.5±3.4 T260G+G328A+T438A 27.4±2.1 93.5±0.7 T260G+G328A+T438D 34.9±3.5 99.4±0.2 T260G+G328A+T438G 27.7±3.1 93.8±0.6 T260G+G328A+T438S 9.3±0.2 99.3±0.1 T260G+G328A+T438V 35.1±2.7 95.3±1.1 T260G+G328A+W72C 30.6±4.1 82.4±1.3 T260G+G328A+W72I 5.8±0.5 99.7±0.1 T260G+G328A+A74D 10.2±0.5 66.2±3.3 T260G+G328A+A74G 37.9±1.8 91.9±0.9 T260G+G328A+L82C 38.4±2.2 87.2±2.6 T260G+G328A+L82D 9.0±1.0 99.5±0.2 T260G+G328A+L82F 50.6±2.1 83.8±3.3 T260G+G328A+L82G 28.6±1.7 95.9±0.6 T260G+G328A+L82I 64.2±1.9 88.4±2.1 T260G+G328A+L82M 61.8±3.1 88.8±0.8 T260G+G328A+L82N 26.4±1.9 93.3±3.1 T260G+G328A+L82S 11.7±1.1 85.2±4.6 T260G+G328A+L82T 24.3±1.9 73.3±3.0 T260G+G328A+L82V 68.3±2.2 96.3±0.6

[0122] Note: The test results in Table 2 were obtained after three parallel reactions under the same reaction conditions. Among them, the conversion rate is defined as: (initial substrate concentration-reaction end substrate concentration) / initial substrate concentration×100%; the selectivity is defined as: 6β-hydroxylation product / total product×100%;

[0123] Combined with the test results in Table 2, WT (LG-23) has the defects of low conversion rate and poor selectivity in the reaction of catalyzing LCA to MDCA. In this example, the key active sites are mutated and modified based on the template (LG-23), and a mutant with significantly improved conversion rate and / or selectivity for catalyzing the 6β-hydroxylation reaction of steroid compounds can be obtained;

[0124] Among them, the conversion rate and selectivity of mutant T260G were significantly improved compared with WT (LG-23);

[0125] The mutant provided in this embodiment can improve the selectivity of steroid compounds to generate 6β-hydroxylated products alone, or can improve the conversion rate of steroid compounds to generate 6β-hydroxylated products alone, or can improve the selectivity and yield of steroid compounds to generate 6β-hydroxylated products at the same time. Therefore, this embodiment overcomes the defects of low conversion rate and / or poor selectivity in the 6β-hydroxylation reaction of steroid compounds catalyzed by the template (LG-23) in the prior art;

[0126] Further combined with the test results in Table 2, this example also simultaneously verifies the effects of other mutants on the conversion rate and selectivity of catalyzing LCA to MDCA; among them, the conversion rates of mutants W72A, L75A, and L82G are further reduced compared to WT (LG-23), and the conversion rate of mutant W330F is improved compared to WT (LG-23), but the selectivity is significantly reduced. Therefore, it can be further explained that the mutation modification of key active sites in this example is not a conventional choice made on WT (LG-23);

[0127] in, Figure 2 HPLC chart of LCA catalyzed by template LG-23; Figure 3 HPLC chart of LCA catalyzed by mutant T260G+G328A+L82V;

[0128] Further combined with Table 2, Figure 2 and Figure 3 It can be seen that the mutant T260G+G328A+L82V not only exhibits better catalytic activity, but also significantly improves selectivity; among them, the conversion rate is increased by 8.5 times and the selectivity can reach 96.3%.

[0129] Embodiment 4:

[0130] Based on the test results of Example 3, this example uses the mutant T260G+G328A+L82V as an exemplary mutant to further verify the enzyme activity of the mutant;

[0131] The method for inducing expression of the mutant in this example is the same as that in Example 1;

[0132] Take 20 μL of the T260G+G328A+L82V recombinant strain stored at -80°C, add it to 5 mL of LB medium containing 50 μg / mL, and culture it overnight at 37°C and 220 rpm. Take 2.5 mL of the bacterial solution and add it to 250 mL of TB medium containing 50 μg / mL kanamycin, and culture it at 37°C and 220 rpm until the OD 600 was 0.6-0.8, 0.2 mM IPTG, 0.5 mM 5-ALA were added, and induced at 20°C, 180 rpm for 20 h;

[0133] The culture solution was collected by centrifugation at 6000 rpm and 4°C for 5 min, washed twice with equilibrium buffer, and the obtained wet cells were stored at -80°C for later use;

[0134] The wet cells collected above were resuspended according to 1 g (wet cells): 15 mL (equilibrium buffer), and ultrasonically disrupted in an ice bath, on for 1 s, off for 2 s, for a total of 45 min. The cell disruption solution was centrifuged at 12000 rpm and 4°C for 15 min, and the supernatant was filtered with a 0.22 μm filter membrane for subsequent purification;

[0135] The purification method is nickel column affinity chromatography: the purification column is a 5 mL pre-packed column, the entire purification system is first equilibrated with equilibration buffer, and then the sample is loaded at a flow rate of 1 mL / min, and the impurities that are not attached to the column are further removed with equilibration buffer, and then gradient elution is performed with elution buffer;

[0136] The target protein was eluted at an imidazole concentration of about 150 mM. The target protein was collected, concentrated and desalted using an ultrafiltration tube (cutoff 50 KDa) to a final volume of 1 mL, and the protein solution was aliquoted and stored at -80°C for later use;

[0137] Because cytochrome P450 BM3 is an NADPH-dependent monooxygenase, NADPH has a maximum UV absorption at 340 nm, while NADP + There is no maximum absorption here, so the activity of the mutants was evaluated by detecting the change in absorbance at 340 nm;

[0138] The specific method is: add 0.8 μM pure enzyme (the above protein solution), 0.5 mM LCA, and 1 mM NADPH to a 250 μL reaction system (100 mM potassium phosphate buffer, pH 7.2), and monitor the change in absorbance within 5 minutes of the reaction. Immediately after the reaction, extract with an equal volume of ethyl acetate, repeat the extraction three times, combine the organic phases, evaporate the solvent with a nitrogen blower, and finally dissolve with an equal volume of methanol, filter with a 0.22 μm filter membrane, and use HPLC to detect the formation of the product. The test results are shown in Table 3. Among them, K cat / K M (M -1 min -1 ) is the catalytic efficiency;

[0139] Table 3: Enzyme activity test results of LG-23 and mutant T260G+G328A+L82V

[0140] Mutants <![CDATA[K m (µM)]]> <![CDATA[k cat (min -1 )]]> <![CDATA[k cat / K m (M -1 my -1 )]]> TON LG-23 - - - 102.3 T260G / G328A / L82V 103.8±28.6 23.9 2.3x105 386.4

[0141] Combined with the test results in Table 3, it can be seen that the mutant T260G+G328A+L82V has better catalytic efficiency than the template LG-23. Among them, the template LG-23 has a low MDCA generation rate, so its kinetic parameters cannot be accurately determined. The turnover number (TON) reflects the stability of the enzyme molecule catalytic reaction. From the TON value, the mutant T260G+G328A+L82V is 3.8 times that of LG-23, and can more stably catalyze LCA to generate MDCA.

[0142] In summary, this example uses the amino acid sequence shown in SEQ ID NO. 2 as a template, performs mutation modification on the key active sites of the template, constructs a mutant library, and screens a series of mutants with significantly improved catalytic activity and / or selectivity; the cytochrome P450 BM3 mutant provided in the example of the present application can selectively catalyze the 6β-hydroxylation reaction of steroid compounds to generate 6β-hydroxylated steroid compounds, and has excellent selectivity and / or high yield, indicating that the mutant has good application prospects in catalyzing steroid compounds to prepare 6β-hydroxysteroid compounds.

[0143] The technical solutions provided in the embodiments of the present application are introduced in detail above. Specific examples are used herein to illustrate the principles and implementation methods of the embodiments of the present application. The description of the above embodiments is only applicable to help understand the principles of the embodiments of the present application. At the same time, for those skilled in the art, according to the embodiments of the present application, there will be changes in the specific implementation methods and application scopes. In summary, the contents of this specification should not be understood as limiting the present application.

Claims

1. A cytochrome P450 BM3 mutant, characterized in that: The mutant has any one of the following amino acid mutations in the amino acid sequence shown in SEQ ID NO. 2: T260G+G328A, T260G+G328S, T260G+W330F, T260G+W330V, T260G+L437M, T260G+T438A, T260G+T438G, T260G+T438S, T260G+T438V, T260G+W72G, T260G+L78A, T260G+L78S, T260G+L82G, T260G+G328A+W330A , T260G+G328A+W330D, T260G+G328A+W330F, T260G+G328A+W330G, T260G+G328A+W330I, T260G+G328A+ W330L, T260G+G328A+W330M, T260G+G328A+W330N, T260G+G328A+W330S, T260G+G328A+W330V, T260G+G 328A+W330Y, T260G+G328A+T438A, T260G+G328A+T438D, T260G+G328A+T438G, T260G+G328A+T438S, T 260G+G328A+T438V, T260G+G328A+W72C, T260G+G328A+W72I, T260G+G328A+A74D, T260G+G328A+A74G, T260G+G328A+L82C, T260G+G328A+L82D, T260G+G328A+L82F, T260G+G328A+L82G, T260G+G328A+L82I, T260G+G328A+L82M, T260G+G328A+L82N, T260G+G328A+L82S, T260G+G328A+L82T, T260G+G328A+L82V.

2. A DNA molecule, characterized in that The DNA molecule is a nucleotide sequence encoding the cytochrome P450BM3 mutant according to claim 1 or its complementary sequence.

3. A recombinant plasmid, characterized in that: The recombinant plasmid contains the DNA molecule as claimed in claim 2.

4. A recombinant strain, characterized in that: The recombinant strain contains the recombinant plasmid as claimed in claim 3.

5. The recombinant strain according to claim 4, characterized in that The host cell of the recombinant strain is a prokaryotic cell or a eukaryotic cell, and the eukaryotic cell is a yeast cell.

6. The recombinant strain according to claim 4, characterized in that The host cells of the recombinant strain are competent cells.

7. The recombinant strain according to claim 6, characterized in that The competent cells are Escherichia coli BL21 (DE3).

8. Use of the cytochrome P450 BM3 mutant according to claim 1, the DNA molecule according to claim 2, the recombinant plasmid according to claim 3, or the recombinant strain according to any one of claims 4 to 7 in catalyzing the 6β-hydroxylation reaction of steroid compounds to generate 6β-hydroxylated steroid compounds.

9. The use according to claim 8, characterized in that The preparation method of the 6β-hydroxylated steroid compound comprises: preparing a recombinant plasmid containing a gene encoding a cytochrome P450 BM3 mutant; Transforming the recombinant plasmid into a host cell to obtain a recombinant strain; Using steroidal compounds as substrates, in the presence of O2 and NADPH, the recombinant strain catalyzes the 6β-hydroxylation reaction of steroidal compounds to obtain 6β-hydroxylated steroidal compounds; The steroid compound is selected from one of the following compounds: ; Wherein, R1, R2, and R3 are selected from any one of the following AK: 。